Scholarlink

Background <p>Colorectal cancer (CRC) ranks high in both global incidence and mortality rates. The discovery of potential biomarkers and therapeutic targets can effectively improve early diagnosis, treatment efficacy, and prognosis for CRC patients.</p> Methods <p>Genes that were abnormally expressed in CRC tumors and associated with patients’ prognosis were first screened in The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases; Clinical CRC samples were used to validate the results. The correlation between clinical characteristics and candidate genes, as well as their role in CRC cell proliferation, migration, invasion capability, and the cell cycle were analyzed.</p> Results <p>The study indicated that glycerol-3-phosphate dehydrogenase 1-like (<i>GPD1L</i>) was significantly down-regulated in CRC tumor tissues and served as an independent prognostic factor for OS and RFS of CRC patients. It was also associated with TNM staging, lymph node metastasis, tumor size, and tumor location. Inhibiting <i>GPD1L</i> expression significantly up-regulated the proliferation, migration, and invasion capabilities of CRC cells.</p> Conclusions <p><i>GPD1L</i> may serve as a prognostic biomarker for patients with CRC and participate in the regulation of CRC cell proliferation, migration, and invasion capability.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Identification of GPD1L as a potential prognosis biomarker and associated with colorectal cancer progression

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月8日

查看全文
  • Ya-Rui Liu,
  • Ying Zeng,
  • Chao Mei,
  • Yun-Hua Xu,
  • Hai-Bo Zhang,
  • Rui Liang,
  • Guo Wang

摘要

Background

Colorectal cancer (CRC) ranks high in both global incidence and mortality rates. The discovery of potential biomarkers and therapeutic targets can effectively improve early diagnosis, treatment efficacy, and prognosis for CRC patients.

Methods

Genes that were abnormally expressed in CRC tumors and associated with patients’ prognosis were first screened in The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases; Clinical CRC samples were used to validate the results. The correlation between clinical characteristics and candidate genes, as well as their role in CRC cell proliferation, migration, invasion capability, and the cell cycle were analyzed.

Results

The study indicated that glycerol-3-phosphate dehydrogenase 1-like (GPD1L) was significantly down-regulated in CRC tumor tissues and served as an independent prognostic factor for OS and RFS of CRC patients. It was also associated with TNM staging, lymph node metastasis, tumor size, and tumor location. Inhibiting GPD1L expression significantly up-regulated the proliferation, migration, and invasion capabilities of CRC cells.

Conclusions

GPD1L may serve as a prognostic biomarker for patients with CRC and participate in the regulation of CRC cell proliferation, migration, and invasion capability.